NASDAQ:DRRX

DURECT Stock Forecast, Price & News

$1.70

+0.02 (+1.19 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.63

▼

$1.71

50-Day Range

$1.60

▼

$1.92

52-Week Range

$1.52

▼

$2.95

Volume1.16 million shs

Average Volume1.53 million shs

Market Capitalization$386.59 million

P/E RatioN/A

Dividend YieldN/A

Beta1.41

30 days | 90 days | 365 days | Advanced Chart

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

About DURECT

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DURECT Co. (NASDAQ:DRRX) Expected to Announce Quarterly Sales of $2.76 Million
June 16, 2021 | americanbankingnews.com

DURECT Corporation Common Stock (DRRX)
June 15, 2021 | nasdaq.com

Analysts Anticipate DURECT Co. (NASDAQ:DRRX) Will Post Earnings of -$0.04 Per Share
June 14, 2021 | americanbankingnews.com

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) - Yahoo Finance
June 9, 2021 | finance.yahoo.com

DURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Buy" from Analysts
June 5, 2021 | americanbankingnews.com

BRIEF-Durect Corp Says On May 28, Co, Oxford Finance Llc Entered Into Fifth Amendment Of $20.0 Million Loan And Security Agreement
June 4, 2021 | msn.com

DURECT Co. (NASDAQ:DRRX) Expected to Post Quarterly Sales of $2.76 Million
May 29, 2021 | americanbankingnews.com

-$0.04 EPS Expected for DURECT Co. (NASDAQ:DRRX) This Quarter
May 27, 2021 | americanbankingnews.com

Durect: Q1 Earnings Insights - Benzinga
May 4, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRRX
Previous Symbol
CUSIPN/A
CIK1082038
Webwww.durect.com
Phone408-777-1417
Employees81
Year FoundedN/A

Sales & Book Value

Annual Sales$30.11 million
Price / Sales12.84
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.20 per share
Price / Book8.50

Profitability

EPS (Most Recent Fiscal Year)($0.07)
Net Income$-580,000.00
Net Margins-2.33%
Return on Equity-28.91%
Return on Assets-16.67%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares227,406,000
Market Cap$386.59 million
Next Earnings Date8/2/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

485th out of 2,100 stocks

Pharmaceutical Preparations Industry

236th out of 830 stocks

3.5 Analyst's Opinion

Consensus Rating
DURECT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.60, DURECT has a forecasted upside of 288.2% from its current price of $1.70.
Amount of Analyst Coverage
DURECT has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
DURECT has received 307 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
DURECT has received 215 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
DURECT has received 58.81% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote “Outperform” if you believe DRRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
DURECT does not currently pay a dividend.
Dividend Growth
DURECT does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DURECT insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,436.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of DURECT is held by insiders.
Percentage Held by Institutions
51.13% of the stock of DURECT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for DURECT are expected to grow in the coming year, from ($0.19) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DURECT is -170.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DURECT is -170.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DURECT has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

DURECT (NASDAQ:DRRX) Frequently Asked Questions

Is DURECT a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT or view top-rated stocks.

What stocks does MarketBeat like better than DURECT?

Wall Street analysts have given DURECT a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DURECT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for DURECT.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Tuesday, May, 4th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.05). The specialty pharmaceutical company had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.63 million. DURECT had a negative net margin of 2.33% and a negative trailing twelve-month return on equity of 28.91%.
View DURECT's earnings history.

How has DURECT's stock price been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DRRX shares have increased by 3.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for DRRX?

6 equities research analysts have issued 12-month target prices for DURECT's shares. Their forecasts range from $5.00 to $8.00. On average, they expect DURECT's share price to reach $6.60 in the next year. This suggests a possible upside of 288.2% from the stock's current price.
View analysts' price targets for DURECT or view top-rated stocks among Wall Street analysts.

Who are DURECT's key executives?

DURECT's management team includes the following people:

Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 64, Pay $775.88k)
Mr. Michael H. Arenberg, CFO & Sec. (Age 51, Pay $452.94k)
Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 64, Pay $406.51k)
Dr. Norman L. Sussman, Chief Medical Officer (Age 68, Pay $419.68k)
Dr. Andrew R. Miksztal, VP of Pharmaceutical R&D and Principal Scientist
Mr. Steve Helmer J.D., VP & Chief Patent Counsel
Dr. WeiQi Lin, Exec. VP of R&D and Principal Scientist
Ms. Jian Li M.B.A., VP of Fin. & Corp. Controller (Age 51)
Dr. Su Il Yum, Exec. Officer (Age 82)

Who are some of DURECT's key competitors?

Some companies that are related to DURECT include PMV Pharmaceuticals (PMVP), Cytokinetics (CYTK), Heron Therapeutics (HRTX), uniQure (QURE), PureTech Health (PRTC), Kura Oncology (KURA), Prelude Therapeutics (PRLD), COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Stoke Therapeutics (STOK), Avid Bioservices (CDMO), Generation Bio (GBIO), Arcutis Biotherapeutics (ARQT), Kronos Bio (KRON) and Innoviva (INVA).
View all of DRRX's competitors.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different institutional and retail investors. Top institutional shareholders include Lion Point Capital LP (6.73%), BlackRock Inc. (6.51%), Lion Point Capital LP (5.65%), Ingalls & Snyder LLC (3.27%), JPMorgan Chase & Co. (1.85%) and Renaissance Technologies LLC (1.72%). Company insiders that own DURECT stock include First Eagle Investment Managem, Judy R Joice and Lp Bleichroeder.
View institutional ownership trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Lion Point Capital LP, Lion Point Capital LP, Renaissance Technologies LLC, Morgan Stanley, Squarepoint Ops LLC, Beirne Wealth Consulting Services LLC, AQR Capital Management LLC, and Credit Suisse AG. Company insiders that have sold DURECT company stock in the last year include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT or view top insider-selling stocks.

Which institutional investors are buying DURECT stock?

DRRX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Dimensional Fund Advisors LP, BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Cambridge Investment Research Advisors Inc., and Barclays PLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, and Lp Bleichroeder.
View insider buying and selling activity for DURECT or or view top insider-buying stocks.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.70.

How much money does DURECT make?

DURECT has a market capitalization of $386.59 million and generates $30.11 million in revenue each year. The specialty pharmaceutical company earns $-580,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

How many employees does DURECT have?

DURECT employs 81 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

Where are DURECT's headquarters?

DURECT is headquartered at 10260 BUBB RD, CUPERTINO CA, 95014.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417 or via email at [email protected]

This page was last updated on 6/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here